Trials / Completed
CompletedNCT05903118
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
A Phase I/II, Randomized, Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (RBMRNA-176) in Healthy Adults Aged 18 Years and Older
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 480 (actual)
- Sponsor
- Argorna Pharmaceuticals Co., LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The phase I/II study is to evaluate the safety and immunogenicity of SARS-COV-2 mRNA Vaccine (RBMRNA-176) at different doses in healthy subjects aged 18 years and older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RBMRNA-176 | Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection |
| OTHER | Placebo | 0.9% sodium chloride (normal saline) injection |
Timeline
- Start date
- 2022-01-08
- Primary completion
- 2022-09-01
- Completion
- 2023-07-19
- First posted
- 2023-06-15
- Last updated
- 2024-01-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05903118. Inclusion in this directory is not an endorsement.